APA (7th ed.) Citation

Madle, M., Krämer, I., Giesen, N., Schwarzbich, M., Wuchter, P., Egerer, G., . . . Witzens-Harig, M. (2014). Rituximab, age and high dose therapy followed by autologus stem cell transplantation are independent prognostic factors for survival in the first line treatment of primary CNS-lymphoma. Blood, 124(21), .

Chicago Style (17th ed.) Citation

Madle, Michael, Isabelle Krämer, Nicola Giesen, Mark-Alexander Schwarzbich, Patrick Wuchter, Gerlinde Egerer, Anthony Dick Ho, and Mathias Witzens-Harig. "Rituximab, Age and High Dose Therapy Followed by Autologus Stem Cell Transplantation Are Independent Prognostic Factors for Survival in the First Line Treatment of Primary CNS-lymphoma." Blood 124, no. 21 (2014).

MLA (9th ed.) Citation

Madle, Michael, et al. "Rituximab, Age and High Dose Therapy Followed by Autologus Stem Cell Transplantation Are Independent Prognostic Factors for Survival in the First Line Treatment of Primary CNS-lymphoma." Blood, vol. 124, no. 21, 2014.